584 filings
8-K
AYTU
Aytu BioPharma Inc
14 Feb 24
Aytu BioPharma Reports Record ADHD Revenue and Operating
4:12pm
10-Q
2024 Q2
AYTU
Aytu BioPharma Inc
Quarterly report
14 Feb 24
4:05pm
8-K
AYTU
Aytu BioPharma Inc
17 Nov 23
Entry into a Material Definitive Agreement
4:10pm
8-K
AYTU
Aytu BioPharma Inc
14 Nov 23
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
4:10pm
10-Q
2024 Q1
AYTU
Aytu BioPharma Inc
Quarterly report
14 Nov 23
4:05pm
8-K
kvs5rk
26 Oct 23
Aytu BioPharma Announces Approval of the Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement
8:05am
8-K
vxgoq nkgt0mxd22
6 Oct 23
Departure of Directors or Certain Officers
4:30pm
NT 10-K
iwtdbzdfaqfo2 gvyon
29 Sep 23
Notice of late annual filing
4:15pm
8-K
j35wa
27 Sep 23
Results of Operations and Financial Condition
4:20pm
8-K
lysuxj
15 Aug 23
Departure of Directors or Certain Officers
4:10pm
8-K
e9by 15tgsfb1brm
31 Jul 23
Regulation FD Disclosure
8:05am
8-K
9xfvf
10 Jul 23
Aytu BioPharma Announces Submission of Cotempla XR-ODT® Manufacturing Site Transfer Prior Approval Supplement
8:05am
S-8
sjvzptl6
23 Jun 23
Registration of securities for employees
4:54pm
8-K
yqas5l2e
12 Jun 23
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
5:19pm
424B4
2u77b5c4y5ztew
12 Jun 23
Prospectus supplement with pricing info
5:12pm
FWP
x6qdy
9 Jun 23
Free writing prospectus
8:10am
EFFECT
gph8gvby3exod380
9 Jun 23
Notice of effectiveness
12:15am
CORRESP
bz1ooytc pi3mptr3dq2
7 Jun 23
Correspondence with SEC
12:00am
CORRESP
7hp o8ibx2ube8yx
7 Jun 23
Correspondence with SEC
12:00am